Bluejay Diagnostics (BJDX) Net Equity Issued and Repurchased (2020 - 2026)

Bluejay Diagnostics (BJDX) reported Net Equity Issued and Repurchased of $125000.0 for Q1 2026, down 97.22% sequentially from $4.5 million in Q4 2025.

Bluejay Diagnostics (BJDX) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends

Bluejay Diagnostics (BJDX) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $125000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $125000.0; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (changed N/A YoY), and the FY2025 full-year result was $8.3 million, down 30.84% from the prior year.
  • Net Equity Issued and Repurchased declined to $125000.0 in Q1 2026, from $4.5 million in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $8.6 million in Q2 2024 to a low of $125000.0 in Q1 2026.
  • A 3-year average of $4.2 million and a median of $4.0 million in 2024 frame the typical range for Net Equity Issued and Repurchased.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 97.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 12.70 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Bluejay Diagnostics 2,754.24 2,754.24 - 125,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 125,000.00
Mar 31, 2026 125,000.00
Dec 31, 2025 4.50 Mn
Dec 31, 2025 4.50 Mn
Jun 30, 2024 8.57 Mn
Jun 30, 2024 8.57 Mn
Mar 31, 2024 3.50 Mn
Mar 31, 2024 3.50 Mn
Dec 31, 2020 -383.00
Dec 31, 2020 -383.00